|
1
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Metzger-Filho O, Tutt A, de Azambuja E,
Saini KS, Viale G, Loi S, et al: Dissecting the heterogeneity of
triple-negative breast cancer. J Clin Oncol. 30:1879–1887. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Paez JG, Janne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, et al: EGFR mutations in lung cancer:
correlation with clinical response to gefitinib therapy. Science.
304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Korsching E, Jeffrey SS, Meinerz W, Decker
T, Boecker W and Buerger H: Basal carcinoma of the breast
revisited: an old entity with new interpretations. J Clin Pathol.
61:553–560. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Baker M: EGFR inhibitors square off at
ASCO. Nat Biotechnol. 22:6412004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cohen EE, Lingen MW, Martin LE, Harris PL,
Brannigan BW, Haserlat SM, et al: Response of some head and neck
cancers to epidermal growth factor receptor tyrosine kinase
inhibitors may be linked to mutation of ERBB2 rather than EGFR.
Clin Cancer Res. 11:8105–8108. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Giusti RM, Shastri K, Pilaro AM, Fuchs C,
Cordoba-Rodriguez R, Koti K, et al: U.S. Food and Drug
Administration approval: panitumumab for epidermal growth factor
receptor-expressing metastatic colorectal carcinoma with
progression following fluoropyrimidine-, oxaliplatin-, and
irinotecan-containing chemotherapy regimens. Clin Cancer Res.
14:1296–1302. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sobrero AF, Maurel J, Fehrenbacher L,
Scheithauer W, Abubakr YA, Lutz MP, et al: EPIC: phase III trial of
cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin
failure in patients with metastatic colorectal cancer. J Clin
Oncol. 26:2311–2319. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Polychronis A, Sinnett HD, Hadjiminas D,
Singhal H, Mansi JL, Shivapatham D, et al: Preoperative gefitinib
versus gefitinib and anastrozole in postmenopausal patients with
oestrogen-receptor positive and
epidermal-growth-factor-receptor-positive primary breast cancer: a
double-blind placebo-controlled phase II randomised trial. Lancet
Oncol. 6:383–391. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Johnston JB, Navaratnam S, Pitz MW,
Maniate JM, Wiechec E, Baust H, et al: Targeting the EGFR pathway
for cancer therapy. Curr Med Chem. 13:3483–3492. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Montemurro F, Valabrega G and Aglietta M:
Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase
activity. Expert Opin Biol Ther. 7:257–268. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Baselga J, Albanell J, Ruiz A, Lluch A,
Gascón P, Guillém V, et al: Phase II and tumor pharmacodynamic
study of gefitinib in patients with advanced breast cancer. J Clin
Oncol. 23:5323–5333. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tan AR, Yang X, Hewitt SM, Berman A,
Lepper ER, Sparreboom A, et al: Evaluation of biologic end points
and pharmacokinetics in patients with metastatic breast cancer
after treatment with erlotinib, an epidermal growth factor receptor
tyrosine kinase inhibitor. J Clin Oncol. 22:3080–3090. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Irwin ME, Mueller KL, Bohin N, Ge Y and
Boerner JL: Lipid raft localization of EGFR alters the response of
cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J
Cell Physiol. 226:2316–2328. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Metro G, Finocchiaro G and Cappuzzo F:
Anti-cancer therapy with EGFR inhibitors: factors of prognostic and
predictive significance. Ann Oncol. (Suppl 2): ii42–ii45.
2006.PubMed/NCBI
|
|
16
|
She QB, Solit D, Basso A and Moasser MM:
Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells
can be overcome through restoration of PTEN function or
pharmacologic modulation of constitutive phosphatidylinositol
3′-kinase/Akt pathway signaling. Clin Cancer Res. 9:4340–4346.
2003.PubMed/NCBI
|
|
17
|
El Guerrab A, Zegrour R, Nemlin CC, Vigier
F, Cayre A, Penault-Llorca F, et al: Differential impact of
EGFR-targeted therapies on hypoxia responses: implications for
treatment sensitivity in triple-negative metastatic breast cancer.
PLoS One. 6:e250802011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu YL, Chou RH, Liang JH, Chang WJ, Su KJ,
Tseng YJ, et al: Targeting the EGFR/PCNA signaling suppresses tumor
growth of triple-negative breast cancer cells with cell-penetrating
PCNA peptides. PLoS One. 8:e613622013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Curto M, Cole BK, Lallemand D, Liu CH and
McClatchey AI: Contact dependent inhibition of EGFR signaling by
Nf2/Merlin. J Cell Biol. 177:893–903. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lazar CS, Cresson CM, Lauffenburger DA and
Gill GN: The Na+/H+ exchanger regulatory
factor stabilizes epidermal growth factor receptors at the cell
surface. Mol Biol Cell. 15:5470–5480. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bretscher A, Chambers D, Nguyen R and
Reczek D: ERM-Merlin and EBP50 protein families in plasma membrane
organization and function. Annu Rev Cell Dev Biol. 16:113–143.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shibata T, Chuma M, Kokubu A, Sakamoto M
and Hirohashi S: EBP50, a beta-catenin-associating protein,
enhances Wnt signaling and is over-expressed in hepatocellular
carcinoma. Hepatology. 38:178–186. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fraenzer JT, Pan H, Minimo L Jr, Smith GM,
Knauer D and Hung G: Overexpression of the NF2 gene inhibits
schwannoma cell proliferation through promoting PDGFR degradation.
Int J Oncol. 23:1493–1500. 2003.PubMed/NCBI
|
|
25
|
Pan Y, Wang L and Dai JL: Suppression of
breast cancer cell growth by Na+/H+ exchanger
regulatory factor 1 (NHERF1). Breast Cancer Res. 8:R632006.
View Article : Google Scholar
|
|
26
|
Cardone RA, Bellizzi A, Busco G, Weinman
EJ, Dell’Aquila ME, Casavola V, Azzariti A, Mangia A, Paradiso A
and Reshkin SJ: The NHERF1 PDZ2 domain regulates
PKA-RhoA-p38-mediated NHE1 activation and invasion in breast tumor
cells. Mol Biol Cell. 18:1768–1780. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Song J, Bai J, Yang W, Gabrielson EW, Chan
DW and Zhang Z: Expression and clinicopathological significance of
oestrogen-responsive ezrin-radixinmoesin-binding phosphoprotein 50
in breast cancer. Histopathology. 51:40–53. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bellizzi A, Malfettone A, Cardone RA and
Mangia A: NHERF1/EBP50 in breast cancer: clinical perspectives.
Breast Care (Basel). 5:86–90. 2010. View Article : Google Scholar
|
|
29
|
Bellizzi A, Mangia A, Malfettone A,
Cardone RA, Simone G, Reshkin SJ and Paradiso A:
Na+/H+ exchanger regulatory factor 1
expression levels in blood and tissue predict breast tumour
clinical behaviour. Histopathology. 58:1086–1095. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mangia A, Chiriatti A, Bellizzi A,
Malfettone A, Stea B, Zito FA, et al: Biological role of NHERF1
protein expression in breast cancer. Histopathology. 55:600–608.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Georgescu M, Morales FC, Molina JR and
Hayashi Y: Roles of NHERF1/EBP50 in cancer. Curr Mol Med.
8:459–468. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gebhardt F, Bürger H and Brandt B:
Modulation of EGFR gene transcription by secondary structures, a
polymorphic repetitive sequence and mutations - a link between
genetics and epigenetics. Histol Histopathol. 15:929–936.
2000.PubMed/NCBI
|
|
33
|
Weinman EJ, Steplock D, Wade JB and
Shenolikar S: Ezrin binding domain-deficient NHERF attenuates
cAMP-mediated inhibition of Na(+)/H(+) exchange in OK cells. Am J
Physiol Renal Physiol. 281:F374–F380. 2001.PubMed/NCBI
|
|
34
|
Weinman EJ, Wang Y, Wang F, Greer C,
Steplock D and Shenolikar S: A C-terminal PDZ motif in NHE3 binds
NHERF-1 and enhances cAMP inhibition of sodium-hydrogen exchange.
Biochemistry. 42:12662–12668. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Busco G, Cardone RA, Greco MR, Bellizzi A,
Colella M, Antelmi E, et al: NHE1 promotes invadopodial ECM
proteolysis through acidification of the peri-invadopodial space.
FASEB J. 24:3903–3915. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chambers AF, Groom AC and MacDonald IC:
Dissemination and growth of cancer cells in metastatic sites. Nat
Rev Cancer. 2:563–572. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mader CC, Oser M, Magalhaes MA,
Bravo-Cordero JJ, Condeelis J, Koleske AJ, et al: An
EGFR-Src-Arg-cortactin pathway mediates functional maturation of
invadopodia and breast cancer cell invasion. Cancer Res.
71:1730–1741. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sebastian S, Settleman J, Reshkin SJ,
Azzariti A, Bellizzi A and Paradiso A: The complexity of targeting
EGFR signalling in cancer: from expression to turnover. Biochim
Biophys Acta. 1766:120–139. 2006.PubMed/NCBI
|
|
39
|
Grandal MV and Madshus IH: Epidermal
growth factor receptor and cancer: control of oncogenic signalling
by endocytosis. J Cell Mol Med. 12:1527–1534. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lo H-W and Hung M-C: Nuclear EGFR
signalling network in cancers: linking EGFR pathway to cell cycle
progression, nitric oxide pathway and patient survival. Br J
Cancer. 94:184–188. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Greco MR, Antelmi E, Busco G, Guerra L,
Rubino R, Casavola V, et al: Protease activity at invadopodial
focal digestive areas is dependent on NHE1-driven acidic pHe. Oncol
Rep. 31:940–946. 2014.
|
